196

Vascular Endothelial Growth Factor Inhibitor

Prescriber Criteria: Consultant Ophthalmologist

Inpatient use:

- Neovascular (wet) age-related macular degeneration (AMD)
- Visual impairment due to choroidal neovascularisation (CNV)
- Visual impairment due to diabetic macular oedema (DME)
- Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)

To be reserved in patients with one of the above-mentioned conditions who are unresponsive to Bevacizumab after 3 injections.

Duration of Approval:
3 months initially
1 year thereafter